W

Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871

Watchlist Manager
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Watchlist
Price: 11.71 CNY -0.26% Market Closed
Market Cap: 1.9B CNY
Have any thoughts about
Wuhan Hvsen Biotechnology Co Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-1 449
Current
39.5
Median
16.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1 449
=
Enterprise Value
2.4B CNY
/
EBIT
-1.6m CNY
All Countries
Close
EBIT Growth EV/EBIT to Growth
CN
W
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Average EV/EBIT: 2 010.8
Negative Multiple: -1 449
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A

See Also

Discover More